よむ、つかう、まなぶ。
03 資料１－１ 帯状疱疹ワクチンファクトシート (76 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40826.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第26回 6／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
(accessed 2024/04/26).
159.
ZOSTAVAXÒ. (Zoster Vaccine Live) package insert.
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM285015.pdf (accessed
2024/04/26).
160.
ZOSTAVAXÒ. (Zoster Vaccine Live) package insert.
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vac cines/ApprovedProducts/UCM132831.pdf (accessed
2024/03/07).
161.
de Oliveira Gomes J, Gagliardi AM, Andriolo BN, et al. Vaccines for preventing herpes zoster in older adults.
Cochrane Database Syst Rev 2023; 10(10): Cd008858.
162.
Gagliardi AM, Andriolo BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane
Database Syst Rev 2019; 2019(11).
163.
Gagliardi AM, Andriolo BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults.
Cochrane Database Syst Rev 2016; 3(3): Cd008858.
164.
Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: A 10 year review of post-marketing safety
experience. Vaccine 2017; 35(52): 7231-9.
165.
Miller ER, Lewis P, Shimabukuro TT, et al. Post-licensure safety surveillance of zoster vaccine live (Zostavax®)
in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Hum Vaccin Immunother
2018; 14(8): 1963-9.
166.
Food and Drug Administration (FDA). Assessment of the risk of Guillain-Barre Syndrome (GBS) following
recombinant zoster vaccine (RZV) in Medicare data. internet, 2021.
167.
Janusz CB, Anderson TC, Leidner AJ, Lee GM, Dooling K, Prosser LA. Projected risks and health benefits of
vaccination against herpes zoster and related complications in US adults. Hum Vaccin Immunother 2022; 18(5):
2060668.
168.
Nelson J. Zoster Vaccine Session: Vaccine Safety Datalink (VSD) update on post-licensure safety monitoring of
recombinant zoster vaccine (RZV, Shingrix). Internet, 2020.
169.
Lai YC, Yew YW. Severe Autoimmune Adverse Events Post Herpes Zoster Vaccine: A Case-Control Study of
Adverse Events in a National Database. J Drugs Dermatol 2015; 14(7): 681-4.
170.
Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety
Datalink study. J Intern Med 2012; 271(5): 510-20.
171.
Mbinta JF, Wang AX, Nguyen BP, et al. Herpes zoster vaccine safety in the Aotearoa New Zealand population: a
self-controlled case series study. Nat Commun 2023; 14(1): 4330.
172.
Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a
randomized trial. Ann Intern Med 2010; 152(9): 545-54.
173.
Baxter R, Tran TN, Hansen J, et al. Safety of Zostavax™--a cohort study in a managed care organization. Vaccine
2012; 30(47): 6636-41.
174.
Arnou R, Fiquet A, Thomas S, Sadorge C. Immunogenicity and safety of ZOSTAVAX(®) approaching expiry
potency in individuals aged ≥50 years. Hum Vaccin 2011; 7(10): 1060-5.
175.
Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster
75
159.
ZOSTAVAXÒ. (Zoster Vaccine Live) package insert.
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM285015.pdf (accessed
2024/04/26).
160.
ZOSTAVAXÒ. (Zoster Vaccine Live) package insert.
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vac cines/ApprovedProducts/UCM132831.pdf (accessed
2024/03/07).
161.
de Oliveira Gomes J, Gagliardi AM, Andriolo BN, et al. Vaccines for preventing herpes zoster in older adults.
Cochrane Database Syst Rev 2023; 10(10): Cd008858.
162.
Gagliardi AM, Andriolo BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane
Database Syst Rev 2019; 2019(11).
163.
Gagliardi AM, Andriolo BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults.
Cochrane Database Syst Rev 2016; 3(3): Cd008858.
164.
Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: A 10 year review of post-marketing safety
experience. Vaccine 2017; 35(52): 7231-9.
165.
Miller ER, Lewis P, Shimabukuro TT, et al. Post-licensure safety surveillance of zoster vaccine live (Zostavax®)
in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Hum Vaccin Immunother
2018; 14(8): 1963-9.
166.
Food and Drug Administration (FDA). Assessment of the risk of Guillain-Barre Syndrome (GBS) following
recombinant zoster vaccine (RZV) in Medicare data. internet, 2021.
167.
Janusz CB, Anderson TC, Leidner AJ, Lee GM, Dooling K, Prosser LA. Projected risks and health benefits of
vaccination against herpes zoster and related complications in US adults. Hum Vaccin Immunother 2022; 18(5):
2060668.
168.
Nelson J. Zoster Vaccine Session: Vaccine Safety Datalink (VSD) update on post-licensure safety monitoring of
recombinant zoster vaccine (RZV, Shingrix). Internet, 2020.
169.
Lai YC, Yew YW. Severe Autoimmune Adverse Events Post Herpes Zoster Vaccine: A Case-Control Study of
Adverse Events in a National Database. J Drugs Dermatol 2015; 14(7): 681-4.
170.
Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety
Datalink study. J Intern Med 2012; 271(5): 510-20.
171.
Mbinta JF, Wang AX, Nguyen BP, et al. Herpes zoster vaccine safety in the Aotearoa New Zealand population: a
self-controlled case series study. Nat Commun 2023; 14(1): 4330.
172.
Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a
randomized trial. Ann Intern Med 2010; 152(9): 545-54.
173.
Baxter R, Tran TN, Hansen J, et al. Safety of Zostavax™--a cohort study in a managed care organization. Vaccine
2012; 30(47): 6636-41.
174.
Arnou R, Fiquet A, Thomas S, Sadorge C. Immunogenicity and safety of ZOSTAVAX(®) approaching expiry
potency in individuals aged ≥50 years. Hum Vaccin 2011; 7(10): 1060-5.
175.
Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster
75